Arterial chemoembolization for hepatocellular carcinoma

Table 1 Clinical characteristcs of patients with hepatocellular carcinoma

Average age in year (range)	49 (24-69)
Sex (male: female)	72:8
Serum AFP level (μmol/L)
< 50	18 (22.5%)
50-399	20 (25%)
> 400	42 (52.5%)
HBsAg+	62 (77.5%)
TBILT(mg/L)	16.9 ± 6.0
ALT(u/L)	68.9 ± 36.6
ALB(g/L)	38.4 ± 4.4
Child’s grade (a:b:c)	30:47:3
Stage (I:II:III:IV)	2:6:62:10

TBILT: bilirubin, ALT: glutamic-pyruvic transaminase, ALB: albumin.

Table 2 Mean doses of embolic agents and anticancer drugs

TSCTV courses	No of patients	Embolic agents		Anticancer drugs
		SBMs (mg)	LUF (mL)	SB (mg)	ACR (mg)	CDDP (mg)
1	80	145.0	22.3	8.7	41.8	80.0
2	72	114.3	13.7	6.9	37.9	75.6
3	56	107.8	15.4	6.5	40.8	76.4
4	24	91.7	11.7	5.5	40.0	80.0
5-6	6	100.0	11.2	6.0	40.0	80.0
Mean	240	111.8	14.9	6.7	40.1	78.4

SB: Sinobufagin

Table 3 Response to TSCTV in evaluated patients

Stage	CR	PR	MR	NC	PD	Total
I	0	0	0	0	0	0
II	0	0	2	2	0	4
III	0	22	36	4	0	62
IV	0	0	3	4	3	19
Response	0	22	41	10	3	76
Percentage	(0%)	(28.9%)	(53.9%)	(13.1%)	(3.9%)

Table 4 Survival of 76 patients undergoing TSCTV

Stage	No of patients	No of survival (year)
		0.5	1	2	3
I	0	0	0	0	0
II	4	4	4	3	2
III	62	62	60	32	19
IV	10	8	2	0	0
Total	76	74	66	35	21
Percentage		(97.4%)	(86.8%)	(46.1%)	(27.6%)

Table 5 Side effects and complication

Side effects and complications	Incidence No.(%)
Fever 38-39 °C	71 (88.7)
> 39 °C	18 (22.5)
Nausea and vomiting	60 (75.0)
Right hypochondrium pain	72 (90.0)
Cholecystitisa	5 (6.2)
Liver abscess	1 (1.2)
Hapatic failure	4 (5.0)
Ascites	6 (7.5)

^aThe floccule was found in gall bladder by US